Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
IFOM ETS - The AIRC Institute of Molecular Oncology
Institut du Cancer de Montpellier - Val d'Aurelle
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Vanderbilt University Medical Center
M.D. Anderson Cancer Center
BeOne Medicines
Amgen
Abramson Cancer Center at Penn Medicine
Merck Sharp & Dohme LLC
Dartmouth-Hitchcock Medical Center
University of California, San Francisco
National Cancer Center Hospital East
Milton S. Hershey Medical Center
Daiichi Sankyo
University of Kansas Medical Center
Emory University
Pierre Fabre Medicament
Ohio State University Comprehensive Cancer Center
University of California, San Francisco
Freenome Holdings Inc.
City of Hope Medical Center
Bristol-Myers Squibb
NantCell, Inc.
Massachusetts General Hospital
Institut du Cancer de Montpellier - Val d'Aurelle
Alaska Native Tribal Health Consortium
Sotio Biotech Inc.
Alaunos Therapeutics
Vedanta Biosciences, Inc.
Eisai Inc.
Incyte Corporation
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Dartmouth-Hitchcock Medical Center
Bristol-Myers Squibb
Day One Biopharmaceuticals, Inc.
Enterome
New Mexico Cancer Research Alliance
Sanofi
Merck Sharp & Dohme LLC
NuCana plc
National Cancer Institute (NCI)
Elicio Therapeutics
University of California, San Diego
Duke University